中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (1): 85-89.doi: 10.35541/cjd.20210303

• 综述 • 上一篇    

卡波西肉瘤治疗研究新进展

高艳    王鹏    康晓静   

  1. 新疆维吾尔自治区人民医院皮肤科  新疆皮肤病研究重点实验室(XJYS1707),乌鲁木齐  830001
  • 收稿日期:2021-04-18 修回日期:2021-06-28 发布日期:2024-01-05
  • 通讯作者: 康晓静 E-mail:drkangxj666@163.com
  • 基金资助:
    新疆维吾尔自治区创新环境(人才、基地)建设专项“天山创新团队计划”项目(2020D14006)

Treatment of Kaposi′s sarcoma

Gao Yan, Wang Peng, Kang Xiaojing   

  1. Department of Dermatology, People′s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Key Laboratory of Dermatology Research (XJYS1707), Urumqi 830001, China
  • Received:2021-04-18 Revised:2021-06-28 Published:2024-01-05
  • Contact: Kang Xiaojing E-mail:drkangxj666@163.com
  • Supported by:
    Innovation Environment (Talent and Base) Construction Specific Project of Xinjiang Uygur Autonomous Region: "Tianshan Innovative Team Plan"(2020D14006)

摘要: 【摘要】 卡波西肉瘤(KS)的发生与KS相关疱疹病毒(KSHV)感染内皮细胞密切相关。感染KSHV后可表现为各种类型KS,不同分型的临床特点、病情严重程度及预后各有差异。经典型病变局限、病情发展缓慢,艾滋病相关型、地方型侵袭性强,医源型在治疗的同时需控制原发病。应根据KS的临床分型及临床特点制定个体化治疗方案。本文综述KS的治疗方案及研究进展。

关键词: 肉瘤, 卡波西, 药物疗法, 生物疗法, 抗逆转录病毒治疗, 高效

Abstract: 【Abstract】 The occurrence of Kaposi′s sarcoma (KS) is closely related to Kaposi′s sarcoma-associated herpesvirus (KSHV) infection of endothelial cells. KSHV infection can present as various types of KS, and clinical features, severity and prognosis differ among different types of KS. Classic KS is characterized by localized lesions and slow progression, AIDS-related KS and endemic KS are highly aggressive, and iatrogenic KS needs control of the primary disease during treatment. Therefore, individualized therapies should be developed according to the clinical classifications and characteristics of KS. This review summarizes treatment modalities of and research progress in KS.

Key words: Sarcoma, Kaposi, Drug therapy, Biological therapy, Antiretroviral therapy, highly active

引用本文

高艳 王鹏 康晓静. 卡波西肉瘤治疗研究新进展[J]. 中华皮肤科杂志, 2024,57(1):85-89. doi:10.35541/cjd.20210303

Gao Yan, Wang Peng, Kang Xiaojing. Treatment of Kaposi′s sarcoma[J]. Chinese Journal of Dermatology, 2024, 57(1): 85-89.doi:10.35541/cjd.20210303